Venus Remedies' R3SET Expands Consumer Healthcare Into Wellness Sector

R3SET's pain-relief product range, including gels, emulsions, sprays, and tablets, integrates natural enhancements and nano-tech formulations, showcasing a fusion of technology with natural painkillers.

In a strategic move, Haryana-based pharmaceutical company Venus Remedies has revamped its consumer healthcare division, R3SET, to make a significant entry into the wellness sector. 

The Indian Consumer Healthcare market, valued at INR 42,392 Cr in 2023 with a projected 4-5% Compound Annual Growth Rate (CAGR) until 2028, sets the backdrop for this transformative shift.

Commenting on the same, Saransh Chaudhary, president of consumer healthcare at Venus Remedies, highlighted that R3SET's foray into wellness signifies more than an expansion. 

He said, "Our products and brand are tailored to embrace wellness as a daily practice, seamlessly fitting into consumers' lives. This strategic move reflects our dedication to making wellness a part of everyday life for our consumers."

Under its wellness initiative, R3SET introduced Detox Candies, blending natural herbs including Kalmegh, Punarnava, Daru Haldi, Manjistha, and Guduchi. Positioned as effective liver detoxifiers and stress relievers, these candies respond to the growing demand for health-conscious products.

R3SET's pain-relief product range, including gels, emulsions, sprays, and tablets, integrates natural enhancements and nano-tech formulations, showcasing a fusion of technology with natural painkillers.

In line with environmental responsibility, R3SET adopted eco-friendly packaging and collaborated with Forest Stewardship Council (FSC)-certified vendors. The rebranding aims to establish R3SET as a key player in the holistic healthcare and wellness sector, aiming for seamless integration of wellness into daily life.

Venus Remedies, a global pharmaceutical company founded in 1989, operates in 70 countries with a portfolio of over 500 Marketing Authorizations from regulated and emerging markets.

In October, Venus Remedies received market approval for Bleomycin 15,000 IU Powder for Solution for Injection/Infusion in the United Kingdom, through its subsidiary Venus Pharma GmbH, based in Germany. 

This medication, designed to combat cancer, has versatile applications, including managing squamous cell carcinomas in regions such as the head and neck, cervix, and external genitalia.

In other developments, Venus Remedies launched Elores, a novel antibiotic formulation in Ecuador, South America, as part of efforts to combat multidrug-resistant infections. 

Additionally, in September, the company expanded its oncology portfolio in South Eastern Europe, securing 511 marketing approvals for its oncology products across 66 countries, demonstrating its commitment to enhancing global healthcare.